RT Journal Article
SR Electronic
T1 Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still’s Disease. An Open, Randomized, Multicenter Study
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 2008
OP 2011
DO 10.3899/jrheum.111549
VO 39
IS 10
A1 DAN NORDSTRÖM
A1 ANN KNIGHT
A1 REIJO LUUKKAINEN
A1 RONALD van VOLLENHOVEN
A1 VAPPU RANTALAIHO
A1 ANNA KAJALAINEN
A1 JOHAN G. BRUN
A1 ANNE PROVEN
A1 LOTTA LJUNG
A1 HANNU KAUTIAINEN
A1 TOM PETTERSSON
YR 2012
UL http://www.jrheum.org/content/39/10/2008.abstract
AB Objective. To study the efficacy of anakinra versus disease-modifying antirheumatic drugs (DMARD) in refractory adult-onset Still’s disease (AOSD). Methods. In a 24-week study, 22 patients with AOSD taking prednisolone ≥ 10 mg/day received anakinra (n = 12) or DMARD (n = 10). The primary endpoint was achievement of remission. Results. At 8 and 24 weeks, 7/12 and 6/12 receiving anakinra and 5/10 and 2/10 receiving DMARD achieved remission. Anakinra induced greater improvement in physical health measured by Medical Outcomes Study Short-Form 36 (SF-36; p < 0.011). During an open-label extension (OLE) of 28 weeks, 7/14 patients taking anakinra and 2/3 taking DMARD were in remission. Conclusion. Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the OLE phase. (ClinicalTrials.gov Protocol Registration NCT01033656).